Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Astellas Pharma, Inc.

http://www.astellas.com

Latest From Astellas Pharma, Inc.

Virus-Hit Astellas Cuts Forecast

Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.

Coronavirus COVID-19 Commercial

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

Amgen Has Relatively Smooth Sailing In Q2 Despite COVID-19 Headwinds

Amgen reported a 6% year-over-year increase in second quarter sales despite pandemic-related declines for several drugs as newer product gains and Otezla righted a rocky ship.

Sales & Earnings Business Strategies

Xospata Reimbursement Marks A First For AML In England

NICE has become the first reimbursement body in Europe to appraise and recommend Astellas Pharma’s drug for relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.

United Kingdom Cost Effectiveness
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced Cell Technology, Inc.
    • Agensys, Inc.
    • Audentes Therapeutics, Inc.
    • Fujisawa GmbH
    • Ganymed Pharmaceuticals AG GmbH
    • Mytogen, Inc.
    • Nanna Therapeutics Limited
    • Perseid Therapeutics LLC
    • Potenza Therapeutics Inc.
    • Ocata Therapeutics, Inc.
    • OSI Pharmaceuticals, LLC (Cell Pathways
    • Prosidion)
    • Yamanouchi Pharmaceutical Co., Ltd.
    • Ogeda S.A.
    • Mitobridge, Inc.
    • Mitokyne, Inc.
    • Quethera Limited
    • Universal Cells, Inc.
    • Xyphos Biosciences, Inc.
UsernamePublicRestriction

Register